A phase I trial of recobinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy

A phase I trial of recobinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy

Saved in:
Bibliographic Details
Published in:Blood Vol. 87; no. 9; pp. 3615 - 3624
Main Authors: GORDON, M. S, MCCASKILL-STEVENS, W. J, SLEDGE, G. W, BATTIATO, L. A, LOEWY, J, LOESCH, D, BREEDEN, E, HOFFMAN, R, BEACH, K. J, KUCA, B, KAYE, J
Format: Journal Article
Language:English
Published: Washington, DC The Americain Society of Hematology 1996
Subjects:
Biological and medical sciences
Drug toxicity and drugs side effects treatment
Medical sciences
Pharmacology. Drug treatments
Toxicity: blood
Antineoplastic agent
Human
Thrombocytopenia
Drug combination
Toxicity
Interleukin 11
Hemopathy
Malignant tumor
Dose activity relation
Prevention
Mammary gland diseases
Chemotherapy
Platelet
Phase I trial
Female
Subcutaneous administration
Mammary gland
Recombinant protein
Platelet derived growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0006-4971
1528-0020